BTG plc, a specialist healthcare company, acquires, develops, and commercializes pharmaceutical products worldwide. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers oncology products, including Beads and TheraSphere for the treatment of liver tumours; pulmonology products comprising RePneu Coil system for the treatment of emphysema; and vascular products, such as EkoSonic for severe blood clots, as well as Varithena for moderate to severe varicose veins. The Specialty Pharmaceuticals segment provides acute care and antidote products, such as CroFab for crotalid snakebites; DigiFab for digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment offers Abiraterone acetate for advanced prostate cancer; Alemtuzumab for multiple sclerosis; and Two-Part Hip Cup for hip replacement. BTG plc is also developing uridine triacetate that is in late-stage of clinical trials for life-threatening toxic side effects of overexposure to the chemotherapeutic 5-fluorouracil. The company also manufactures and commercializes therapeutic ultrasound devices. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
btg plc (BTG:London)
5 Fleet Place
London, EC4M 7RD
Phone: 44 20 7575 0000
Fax: 44 20 7575 0010www.btgplc.com
|Impax Laboratories Inc||$33.76 USD||-1.14|
|Merit Medical Systems Inc||$15.72 USD||-0.49|
|Pfizer Ltd/India||2,208 INR||-28.85|
|Sirtex Medical Ltd||A$35.40 AUD||-0.29|
|Medicines Co/The||$31.00 USD||-1.86|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.